XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Corporation will have its CEO, Jim Neal, present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:00 AM ET. The conference aims to highlight XOMA's role as a biotechnology royalty aggregator, helping companies enhance human health by acquiring future economic rights linked to pre-commercial therapeutic candidates. A live stream of the presentation will be accessible here and on XOMA's website. A replay will be available for 90 days post-event.

XOMA Corporation reported its second quarter 2022 financial results, achieving total revenues of $1.0 million, up from $0.9 million in Q2 2021. The net loss widened to $4.7 million compared to $2.2 million in the prior year. Cash at the end of June stood at $83.2 million, with no debt, which management believes will sustain operations for several years. The acquisition of Checkmate Pharmaceuticals resulted in a $2.5 million payment to XOMA, while Rezolute and Day One plan to advance to Phase 3 clinical trials, signaling positive progress in their pipelines.

XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for holders of its Series A and B Cumulative Preferred Stock. Shareholders of the 8.625% Series A stock will receive $0.53906 per share, while holders of the 8.375% Series B stock will receive $0.52344 per depositary share. The dividends are scheduled for payment on July 15, 2022, to shareholders on record by July 1, 2022. XOMA plays a significant role as a biotechnology royalty aggregator, managing over 70 assets related to therapeutic candidates, providing crucial funding for biotech advancement.

XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 AM ET. The presentation will be accessible online and archived for 90 days post-event. XOMA focuses on acquiring potential future earnings from pre-commercial therapeutic candidates, providing non-dilutive funding to sellers. The company's portfolio includes over 70 assets associated with drug products in development, underscoring its impact on improving human health.

XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance for Q1 2022, with total revenues of $3.1 million, up from $0.4 million in Q1 2021. This increase was propelled by a $2 million milestone from Rezolute for the RZ358 study. The company concluded Q1 2022 with cash and restricted cash totaling $88.6 million and no debt. Notably, XOMA recognized a net loss of $2.3 million, a significant improvement compared to a $7.4 million loss in the prior year. The firm remains optimistic about its financial stability and future operations.

XOMA Corporation (Nasdaq: XOMA) announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share, while holders of depositary shares representing 1/1000 of the Series B Cumulative Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per share. The dividends will be paid on or about April 15, 2022, to shareholders on record as of April 1, 2022.

On March 10, 2022, XOMA Corporation (Nasdaq: XOMA) announced that Chairman and CEO Jim Neal will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 12:40 PM ET. This virtual event can be accessed through a direct link or via the investor relations section of XOMA's website, where a replay will be available for 90 days. XOMA specializes in acquiring future royalties from pre-commercial therapeutic candidates, providing non-dilutive funding to biotech companies. The company has an extensive portfolio with over 70 assets.

XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance in 2021, earning $36.2 million in milestone payments and achieving positive operating cash flow for the second consecutive year. Key highlights include a $35 million milestone from its Anti-TGFβ Antibody License Agreement with Novartis. Total revenues reached $38.2 million in 2021, up from $29.4 million in 2020. The company ended the year with $95.4 million in cash and no debt. Significant advances include commercialization approval for a bispecific antibody and progress in multiple drug candidates. CEO succession planning is underway.

XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference. The event is scheduled for March 7, 2022, at 1:30 PM ET. Investors can access the presentation live or via a replay on the company's website for 90 days post-event. XOMA plays a crucial role in advancing human health by acquiring potential future economics from pre-commercial therapeutic candidates, boasting a portfolio of over 70 assets.